GGrantIndex
← Search

Comprehensive Cancer Center Program at Fox Chase

$8,151,999P30FY2005CANIH

Fox Chase Cancer Center, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567Paper 39602533Paper 39554190Paper 39546469Paper 39521739Paper 39514554Paper 39371220Paper 39345610Paper 39343653Paper 39223207Paper 39207123Paper 39189642Paper 39148468Paper 39137728Paper 39072643Paper 39060143Paper 39013784Paper 39003201Paper 38982062Paper 38976159Paper 38963567Paper 38914477Paper 38871720Paper 38865671Paper 38853421Paper 38835516Paper 38815457Paper 38811332Paper 38798370Paper 38766032Paper 38747616Paper 38678525Paper 38659828Paper 38639476Paper 38638131Paper 38600381Paper 38586274Paper 38586042Paper 38559274Paper 38547779Paper 38539515Paper 38464238Paper 38452871Paper 38432028Paper 38421650Paper 38377387Trial NCT04290585Trial NCT03177057Trial NCT02594826Trial NCT02132884Trial NCT02132858Trial NCT02132845Trial NCT02110953Trial NCT02092714Trial NCT02050009Trial NCT01982591Trial NCT01962948Trial NCT01934179Trial NCT01840150Trial NCT01462630Trial NCT01316757Trial NCT01212822Trial NCT00750009Trial NCT00509626Trial NCT00458588Trial NCT00436397Trial NCT00433524Trial NCT00084591Trial NCT00084539Trial NCT00084526Trial NCT00084513Trial NCT00066677Trial NCT00062322Trial NCT00062309Trial NCT00043108Trial NCT00039520Trial NCT00039507Trial NCT00022308Trial NCT00021398Trial NCT00021372Trial NCT00021346Trial NCT00021333Trial NCT00021320Trial NCT00005037Trial NCT00003264Trial NCT00003263Trial NCT00003109Patent 9533040Patent 9182383Patent 9101603Patent 8980258Patent 8685658Patent 8609437Patent 8580263Patent 8329873Patent 7332585Patent 7332580Patent 7129057Patent 6946275Patent 6617427

Abstract

DESCRIPTION (provided by applicant): For the 100 years of its history, Fox Chase Cancer Center (FCCC) has been guided by a singular mission to reduce the burden of human cancer. Its 1904 hospital charter called for "the study of the cause, treatment and prevention of cancer and for the dissemination of knowledge of these subjects. The treatment of cancer patients shall be administered without regard to race, creed or color." One hundred years later, the Center continues as one of the nation's comprehensive cancer centers, one of only a few free-standing centers in the country. During the last CCSG cycle, the Center has completed and opened a new 120,000 square foot Cancer Prevention Pavilion and finished construction of a new 17,000 square foot addition of a Clinical Investigation and Treatment Facility. We have made a major effort to expand our translational research and cancer-relevant science with the appointment of a Vice President for Translational Research, the development of a Translational Research Facility, and the use of all of our pilot project funds for translational research. Total institutional investment in the cancer research science, facilities, equipment, and buildings at Fox Chase during the last Core grant cycle was $173 million. We have recruited 35 new investigators, and of those here over 24 months, 22 of 24 (91 percent) have peer-reviewed funding totaling $7.42 million. Total peer-review funding at FCCC has increased from $32.7 million in 1999 to $49.3 million in 2004, a 50.7 percent increase, and total NCI funding has increased 42 percent. Growth in funding, space, and investigators has occurred in all three of the Institute's Divisions of Medical Science, Basic Science, and Population Science. We have also completed plans for a major expansion of the entire Center over the next 20 to 25 years which will result in tripling the number of Center investigators and quadrupling Center space. The first step in this process, the construction of the Cancer Research Pavilion with space for 15 to 20 new investigators, will take place during the next Core grant cycle. Developmental fund requests call for the recruitment of 29 new or replacement investigators, support for pilot projects, and investment in up to four new shared facilities. This Cancer Center Support Grant requests continued support for professional personnel, including senior and program leadership, administration, planning and evaluation, and developmental funds, as well as support for 11 established peer-reviewed Research Programs and 32 Shared Facilities.

View original record on NIH RePORTER →